In our study, the observation group showed higher levels of CD3+ and CD4+/CD8+ after 1 month or 3 months of treatment, suggesting that the combined regimen has a significant effect in regulating immunosuppression, which may also be the important mechanisms for the effectiveness of advanced lung cancer. The gene discussed is CD8A; the disease is lung carcinoma.